Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: GlobeNewswire
ZUG, Switzerland, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced data from seven posters that will be presented at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). Pharvaris mourns our distinguished colleague, Prof. Marcus Maurer, who passed away during the development and finalization of these posters. “The totality of data supporting deucrictibant’s potential best-in-class profile in both prophylaxis and on-demand remains consistent and provides compelling validation for its continued clinical development,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “The data presented at ACAAI continue to clinically derisk deucrictibant and contribute to excitement for deucrictibant to become a preferred therapy in HAE.” The CHAPTER-1 Phase 2
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference [Yahoo! Finance]Yahoo! Finance
- Pharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewswire
- Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific MeetingsGlobeNewswire
- Pharvaris to Host Virtual Investor Event on October 23, 2024 [Yahoo! Finance]Yahoo! Finance
- Pharvaris to Host Virtual Investor Event on October 23, 2024GlobeNewswire
PHVS
Earnings
- 8/14/24 - Beat
PHVS
Sec Filings
- 10/31/24 - Form 144
- 10/24/24 - Form 144
- 9/25/24 - Form 6-K
- PHVS's page on the SEC website